BioPlus Acquisition, a blank check company targeting the life sciences industry, raised $200 million by offering 20 million units at $10. The company offered 2 million more units than anticipated. It originally planned to offer 22 million units before lowering the offering in November. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50.
BioPlus Acquisition is led by Chairman and CBO Jonathan Rigby, the Group CEO of autoimmune and allergy biotech Revolo Biotherapeutics, and CEO, CFO, and Director Ross Haghighat, the Founding Partner of Jasper Capital Partners and Chairman of Triton Systems. The company aims to leverage management's experience to target the life sciences industry.
BioPlus Acquisition plans to list on the Nasdaq under the symbol BIOSU. Cantor Fitzgerald acted as sole bookrunner on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
